Abstract 2688
Background
Liver resection is a curative treatment for patients with colorectal liver metastasis (CRLM). However, about 70% patients will experience recurrence after resection. CRLM number and maximum (CRLMmax) size have been associated with recurrence after hepatic resection. Still, association between CRLM minimum (CRLMmin) size and tumor recurrence has never been evaluated. This study aimed to correlate CRLMmin on the liver specimen with recurrence free survival (RFS).
Methods
We retrospectively included all patients who underwent first laparoscopic liver resection for CRLM from January 2000 to November 2018 in a single institution. Patients with extra hepatic evolutive disease were excluded. A CRLMmin cut off was selected using the time-dependent area under the curve (td-AUC) for 1 and 2-year RFS. Cox uni and multivariate models were constructed. Multivariate analysis was completed for factors with a p value ≤ 0.10 upon univariate analysis, or previously known determinant factors. Primary end point was RFS.
Results
Overall, 227 patients were included. Median follow- up was 50 months (6-210), 151 (67%) patients presented with recurrence. The optimal CRLMmin cutoff associated with RFS was 9mm (12 and 24-months td-AUC = 0.56 and 0.52, respectively). Median RFS were respectively 11.9 months (CI 95% 7.1-18.7) in patients with CRLMmin size <9mm and 21.9 months (CI 95% 18.5-30.8) for those with CRLMmin size ≥9mm (p < 0.001). In multivariate analysis, CRLMmin size <9mm was an independent prognostic factor for RFS after adjusting on node-positive primary tumor, preoperative carcinoembryonic antigen ACE ≥5ng/ml, multiple liver metastasis and synchronous or metachronous <12months liver metastasis (HR = 1.6 (1.1-2.4); p < 0.05). Also, CRLMmin size <9mm was independently associated with hepatic RFS (HR = 1.8 (1.2-3,0); p < 0.05) but not extra-hepatic RFS.
Conclusions
The present study suggests that CRLMmin size <9mm on the liver specimen was an independent progonostic factor for worse RFS, particularly associated with poor local control over distant metastasis control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
David Fuks.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2674 - Multicenter Phase I Trial of Trastuzumab Emtansine (T-DM1) in Combination with Non-Pegylated Liposomal Doxorubicin (NPLD) in HER2[+] Metastatic Breast Cancer (MBC). THELMA Study
Presenter: Elena López-Miranda
Session: Poster Display session 2
Resources:
Abstract
1398 - Phase 1 study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumors: primary results of dose-escalation part
Presenter: Noboru Yamamoto
Session: Poster Display session 2
Resources:
Abstract
5818 - Polo-like Kinase 1 inhibitor onvansertib synergizes with paclitaxel in breast cancer carrying p53 mutation
Presenter: Antonio Giordano
Session: Poster Display session 2
Resources:
Abstract
5927 - Phase 1b study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173).
Presenter: Robert Wesolowski
Session: Poster Display session 2
Resources:
Abstract
1695 - Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: results from the AGMT_MBC-Registry
Presenter: Simon Peter Gampenrieder
Session: Poster Display session 2
Resources:
Abstract
1742 - Clinical profile and outcome of HER2 positive breast cancer patients with brain metastases treated with HER2 targeted therapy: Real world experience.
Presenter: Prabhat Bhargava
Session: Poster Display session 2
Resources:
Abstract
1846 - Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: results of single arm phase IV COMACHI study
Presenter: Norikazu Masuda
Session: Poster Display session 2
Resources:
Abstract
5385 - Anti HER-2 Therapies and Left Ventricular Dysfunction The Renaissance Study
Presenter: ANDRES DANIELE
Session: Poster Display session 2
Resources:
Abstract
3320 - Safety and efficacy of T-DM1 in 128 patients with advanced HER2+ breast cancer: The Royal Marsden experience.
Presenter: Nicolò Battisti
Session: Poster Display session 2
Resources:
Abstract
4540 - Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): challenges in assessing effectiveness of treatment sequencing in the real world (RW)
Presenter: Thibaut Sanglier
Session: Poster Display session 2
Resources:
Abstract